Fig. 6

Results of BCMA CAR-T manufacture with optimized T cell selection process in the clinical trial. This figure shows that DPBS was successfully used as the T cell isolation buffer to manufacture anti-BCMA CAR-T cells for 13 patients in phase I clinical trial. a CD14 expression and CD3 expression in patients’ PBMC. b CAR-T cell expansion rate after retroviral transduction. The three patients with excessively low CD3⁺% in their PBMC are marked red, yellow, and green. CAR-T cell expansion duration of each patient was plotted against the percentage of CD14⁺ cells (c) or CD3⁺ cells (d) in PBMC before selection. CAR expression percentage in CD3⁺ cells of each patient plotted against the percentage of CD14⁺ (e) or CD3⁺ (f) cells in their PBMC